Lanean...
Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC)
INTRODUCTION: PDAC is a lethal malignancy with a clear unmet need; almost all patients fail 1(st), 2(nd), and 3(rd) line multi-agent cytotoxic chemotherapy. The mammalian target of rapamycin (mTOR) has been identified as a key signaling node enhancing tumor survival and drug resistance in PDAC, henc...
Gorde:
| Argitaratua izan da: | Expert Opin Investig Drugs |
|---|---|
| Egile Nagusiak: | , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6681663/ https://ncbi.nlm.nih.gov/pubmed/31215251 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/13543784.2019.1632289 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|